The Role Of The Acute Phase Response In Docetaxel Resistance In Hormone-refractory Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$74,365.00
Summary
Prostate cancer is the most common cancer in Australian men. Chemotherapy is used in advanced disease, but is only effective in ~50% of patients. In the first year of my PhD, I identified 8 plasma biomarkers that predict chemotherapy resistance. I plan to characterise how these immune molecules cause chemotherapy resistance using a mouse model of advanced prostate cancer. These markers may allow us to personalise prostate cancer treatment in the future and identify more effective therapies.